Safety and effect of YY2201 tablet for advanced cancer
Part of Cancer clinical trials.
This trial tests a new oral tablet, YY2201, for people with advanced cancer that has stopped responding to other treatments. The goal is to find a safe dose and see if it helps shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have advanced cancer that has not responded to standard treatment, or for which no standard treatment exists.
- You must be generally able to care for yourself (not bedridden).
- Your major organs (bone marrow, liver, kidneys, heart) need to work well enough, as shown by recent lab tests.
- You cannot have had certain cancer treatments in the last 4 weeks (or within a specific time depending on the drug).
- You must be willing to use contraception if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral drug (WJ22096) for people with advanced solid tumors that have stopped responding to or cannot tolerate standard treatments. It may be an option if you are generally healthy enough to take part.
This trial is testing a new oral drug called HW221043 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and how well it works.
This trial studies a new drug called HW071021 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can help shrink or control the cancer.
This trial is testing an investigational drug called SYS6077 to see if it is safe and tolerable for people with advanced solid tumors that have not responded to standard treatments. The goal is to find out if this drug is a safe option for patients who have run out of other choices.
This trial tests a new drug called YL205 for people with certain advanced cancers that have a specific protein (Napi2b) on their cells. It aims to see if the drug is safe and effective.
This trial tests a new drug, YL211, in people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective for cancers like lung, colorectal, stomach, pancreatic, liver, bile duct, and head and neck cancers.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.